Background: Serum chromogranin A (CgA) is routinely used as a biomarker in patients with neuroendocrine neoplasms (NENs). Several conditions and comorbidities may be associated with falsely elevated CgA, often leading to extensive diagnostic evaluation, which may be costly and harmful. The aim of this study was to analyze the effectiveness of the acute octreotide suppression test (AOST) in differentiating falsely elevated serum CgA. Methods: Our prospective study enrolled 45 patients from two different patient cohorts: (1) 29 patients with suspicion or presence of NENs (extensive workup and subsequent biopsy confirmed 16 NENs); (2) 16 consecutive patients admitted via the Emergency Department without NENs (non-NENs). AOST was performed after an overnight fast. Baseline CgA was measured, after which 0.25 mg of octreotide was administered subcutaneously. CgA was measured 3 and 6 h after administration. Results: Baseline CgA levels were similar in NENs and non-NENs. At the end of the AOST, CgA decreased by a median of 83.3% (41.0-127.4) in non-NENs and 13.8% (0.0-43.6) in NENs (p < 0.001). In patients with increased baseline CgA, a decrease in CgA at the 6th hour of < 51.3% had 90.0% sensitivity and 88.9% specificity in detecting NENs. In patients with normal baseline serum CgA, a decrease in CgA at the 3rd hour of < 17.6% had 83.3% sensitivity and 81.8% specificity in detecting patients with NENs. The diagnostic accuracy of the AOST in the entire study population was 86.7%. Conclusions: AOST is a promising tool to increase the diagnostic accuracy of serum CgA.
Chromogranin A (CgA) is routinely used only in the diagnosis and follow-up of patients with neuroendocrine neoplasms (NENs) [1] . NEN tumor cells secrete CgA, which has a diagnostic, predictive and prognostic role in this population of patients [1] . However, increased serum CgA can be found in patients with sepsis [2] , acute exacerbation of rheumatoid arthritis [3] , inflammatory bowel disease [4] , various metastatic malignancies [5] , heart and renal failure [6, 7] , complicated myocardial infarction [8] , arterial hypertension [9] , and chronic atrophic gastritis [10] . Moreover, the use of proton pump inhibitors (PPIs) may also increase CgA serum levels [11] .
Due to its nonspecific nature, the exact diagnostic accuracy of CgA as a screening method in detecting patients with NENs remains controversial. Sensitivity of CgA ranges from 53 to 85%, while specificity ranges from 84 to 96% in detecting patients with NENs in the general population [12] . This greatly differs between studies, depending mainly on the control group. Studies focusing on the diagnostic accuracy of CgA may be distinguished from those which exclude or include subjects with interfering factors. Studies that used healthy blood donors had highest diagnostic accuracy of CgA in detecting NENs, while the diagnostic accuracy substantially decreased when the control group consisted of patients using PPIs or patients with other malignant diseases [1, 12] . Moreover, in a study by Marotta et al. [13] that included 42 subjects with NEN, 120 subjects with nonendocrine neoplasias, and 100 nonneoplastic subjects with benign nodular goiter, serum CgA had no diagnostic value in detecting patients with NENs.
The role of the acute octreotide suppression test (AOST) in predicting long-term disease control has been extensively studied in patients with acromegaly, but with conflicting results. The dose of octreotide used in the AOST varied between 0.05 and 0.1 mg. The AOST seemed useful in predicting response to long-acting somatostatin analogue if the nadir growth hormone concentrations were used to interpret the AOST, but it showed no predictive value when the test was interpreted as relative change in serum growth hormone levels [14] .
So far, only three studies have analyzed the role of the AOST as a prognostic factor in patients with NENs [15] [16] [17] . The most representative was a study by Massironi et al. [17] , which showed that a decrease in serum CgA of > 30% during the AOST with 0.2 mg of subcutaneous octreotide was associated with greater overall survival and more favorable response to long-term octreotide treatment. Serum CgA is influenced by a wide variety of both physiological and pathological factors. It is often hard to determine the etiology of increased CgA in a real patient: is it a consequence of comorbidities or "autonomous" hypersecretion from NENs? Dynamic testing is the cornerstone of modern endocrinology designed to deal with diagnosis of diseases caused by hormone hypersecretion. Although it seems logical that the AOST might help in differentiating the cause of increased serum CgA, neither study has analyzed the difference in response to the AOST between patients with falsely increased serum CgA and patients with NENs.
We hypothesized that patients without NENs (nonNENs) have a more pronounced decrease in serum CgA during the AOST, and that the AOST is superior to single CgA measurement in detecting patients with NENs.
Methods
This prospective study included two different patient cohorts. The first cohort consisted of consecutive patients referred to our institution due to suspicion or presence of NEN (n = 29). All these patients underwent computed tomography (CT) and/or magnetic resonance imaging (MRI) and 99m Tc-Tektrotyd scintigraphy. 18 Ffludeoxyglucose positron emission tomography was performed in 2 patients. CT protocols included early arterial phase sequences and MRI protocols included both contrast-enhanced and diffusion-weighted sequences. After the following diagnostic workup and subsequent biopsy, NEN was confirmed in 16 patients and the other 13 patients were labeled as controls.
The second cohort included 16 randomly selected patients admitted via the Emergency Department due to various diseases. The AOST had been performed within the last 2 days of hospitalization. Extensive aforementioned diagnostic workup has not been performed in the second cohort due to a low incidence of NENs in the general population and consequent low probability that some of these randomly selected patients from the Emergency Department had NEN.
Patients who underwent curative surgery and did not have radiological evidence of recurrence or metastases were excluded from the study.
Patients with NENs were classified based on the ENETS guidelines of 2012 [18] . Medical history was analyzed in detail for non-NEN patients. Based on previous reports regarding comorbidities that may affect serum CgA levels, they were labeled with one of the following which was considered to have the highest impact on serum CgA: acute infection, malignant disease apart from NEN, autoimmune disease, other chronic noninfectious diseases (2 or more: diabetes mellitus, arterial hypertension, chronic obstructive pulmonary disease, chronic renal failure, chronic heart failure), and PPI use.
The AOST was performed after an overnight fast and all patients were required to fast during the test. Plasma CgA was measured at baseline, after which octreotide 250 μg was administered subcutaneously. In order to lower the costs of the study, we have DOI: 10.1159/000492934 divided one ampoule of Sandostatin 0.5 mg and performed the test simultaneously in 2 different patients. Venous blood samples were drawn 3 and 6 h after octreotide administration. The CgA level was measured via ELISA using a commercially available kit (Demeditec Diagnostics GmbH, Germany). Blood samples were collected by venipuncture into serum separator tubes without anticoagulant. Serum was separated by centrifugation and immediately stored at −20 ° C until analysis, which was performed as described in the manufacturer's instructions. The normal range was considered to be 12.5-100 μg/L, as provided by the manufacturer. Elevated serum CgA was considered to be > 100 μg/L.
The study was conducted according to the Declaration of Helsinki and was approved by the ethics committee of the University Hospital Center Sisters of Charity. All patients gave their written informed consent to the study.
Statistical Analyses
Patient characteristics were analyzed with descriptive statistics and presented as a median and interquartile range. Since the majority of parameters did not follow normal distribution, we used nonparametric tests as follows: independent continuous variables were compared with the Mann-Whitney U test and categorical variables were compared using Fisher's exact test. Receiver operating characteristic (ROC) analysis was used to analyze the diagnostic accuracy of CgA at each point during the AOST. The results of the (receiver operating characteristic) analysis were presented with the area under the curve (AUC), 95% confidence interval, sensitivity and specificity for each CgA cutoff. Two-tailed p values < 0.05 were considered significant. Statistical analyses were performed by using SPSS Version 20.0 and MedCalc Version 14.8.1.
Results
There were no differences in demographic characteristics and serum CgA levels between non-NEN and NEN patients. Age and gender were not associated with plasma CgA levels or with the magnitude of change in plasma CgA during the AOST. Non-NEN patients had a more pronounced decrease in serum CgA (Table 1 ; Fig. 1 ). Characteristics of patients with NENs are presented in Table 2 . A total of 7 patients were taking PPIs prior to the AOST (5 patients admitted via the Emergency Department and 2 patients with suspicion of NEN; the presence of NEN was excluded after the workup). Among patients taking PPIs, 5 had increased baseline serum CgA and 2 patients had normal CgA. Non-NEN patients had the following factors and comorbidities that might be associated with serum CgA: PPI use in 5 (17.2%), acute infection in 5 (17.2%), autoimmune diseases in 7 (24.1%), other chronic noninfectious diseases in 8 (27.6%) patients, and other malignant disease in 4 (13.8%) patients.
Patients with increased baseline serum CgA had a more pronounced decrease in serum CgA during the AOST although it did not reach statistical significance (-74 In the current study population, single measurement of CgA did not have any diagnostic accuracy in detecting NENs (AUC 0.477, 95% CI 0.296-0.659, p = 0.803).
In patients with increased baseline serum CgA, the decrease in serum CgA at the 6th hour of the AOST of < 51.3% had a 90.0% sensitivity and 88.9% specificity in detecting patients with NEN (AUC 0.906, 95% CI 0.790-1.000). There was only 1 false-negative patient with localized G3 rectal neuroendocrine carcinoma (NEC) and serum neuron-specific enolase (NSE) of 110.3 ng/mL (normal range < 15 ng/mL). There were 2 false-positive patients, a 65-year-old male patient admitted due to diabetic ketoacidosis and sepsis and a 24-year-old female who was admitted due to increased serum CgA and nonspecific dermatitis. All 5 patients who were taking PPIs and had increased baseline CgA had a decrease in serum CgA of > 51.3% (median 94.5% [78. 8-143.4 
]).
In patients with normal baseline serum CgA, the decrease in serum CgA at the 3rd hour of the AOST of < 17.6% had a 83.3% sensitivity and 81.8% specificity in detecting patients with NENs (AUC 0.788, 95% CI 0.544-1.000). There was only 1 false-negative patient with metastatic G2 rectal NEN (Ki-67 8%) who had features of G3 NEN with large necrotic liver metastases and a serum NSE of 28.5 ng/mL. There were 2 false-positive patients admitted via the Emergency Department due to pulmonary embolism and metastatic gastric adenocarcinoma (Fig. 2b) . Two patients with normal baseline CgA while taking PPIs had a decrease in serum CgA of 50.7 and 33.8%, respectively.
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Suspicion or presence of NEN n = 28 Fig. 1 . Flowchart of the study population. The diagnostic performance of AOST is presented in Table 3 . Overall, the diagnostic accuracy of the AOST in the entire study population was 86.7% (Fig. 3) . In a subgroup analysis, there was a trend of higher diagnostic accuracy in patients with pancreatic NENs, as well as in patients with G1 and G2 NENs and patients with metastatic disease, but these differences were not statistically significant due to the small sample size (Table 4) .
Discussion
To the best of our knowledge, this is the first study which analyzed the diagnostic performance of the AOST in detecting patients with NENs. We have shown that the AOST has excellent diagnostic performance in patients with increased baseline plasma CgA. In these patients, the decrease in serum CgA of < 51.3% 6 h after octreotide administration had 91% diagnostic accuracy in detecting patients with NEN. Surprisingly, our results suggest that the AOST may play an important role in patients with normal baseline serum CgA, since the decrease in serum CgA of < 17.6% 3 h after octreotide administration had 79% diagnostic accuracy in detecting patients with NEN. This means that the AOST has excellent performance in detecting patients with falsely increased serum CgA, but might have an important role in detecting patients with NENs and normal baseline serum CgA. The difference in response to the AOST between NEN patients with normal and increased baseline serum CgA was observed by Kos-Kudła et al. [16] . Their study included 32 patients with gastroenteropancreatic and lung neuroendocrine tumors (NETs) and serum CgA was measured 30, 60, 90, and 120 min after 0.1 mg octreotide injection. Patients with increased baseline serum CgA had a significant decrease in serum CgA. On the other hand, serum CgA did not change in patients with baseline normal serum CgA. Interestingly, in patients with increased baseline serum CgA, 25% of patients had a decrease in serum CgA > 60% at the end of the test. A study by Massironi et al. [17] included 38 patients with gastroenteropancreatic NENs and plasma CgA was measured 3 and 6 h after 0.2 mg octreotide injection; approximately 50% of all patients had a decrease in plasma CgA of > 50%. Findings from both of these studies greatly differ from our results, suggesting that our AOST would have too many false-negative results. However, several methodological differences between these studies make such conclusions impossible. For instance, we used a different laboratory technique for serum CgA measurement and therefore any comparisons in serum CgA during the AOST and cutoff values with other studies are difficult [19, 20] . Our AOST protocol was similar to the one reported by Massironi et al. [17] . However, participants in our study were required to fast during the test and not to take PPIs prior to the test, both of which has not been specified in the aforementioned study. This may be important since both feeding and PPIs may influence serum CgA levels [11, 21] . Moreover, patients with poorly differentiated tumors, large tumor burden, and poor functional status were excluded from their study, which might be important when interpreting AOST results.
Only 2 patients with NEN had a false-negative result of the AOST (a decrease in serum CgA > 51% and both had rectal NENs). One patient had localized G3 NEC (Ki-67 90%) and profoundly increased serum NSE levels. We can hypothesize that mildly increased baseline serum CgA was not caused by autonomous tumor secretion, but rather with systemic response to highly malignant disease [22, 23] . In this setting, one would expect to see pronounced decrease in serum CgA during the AOST. The other patient had metastatic G2 rectal neuroendocrine tumors with a tumor burden of > 75%. Her baseline serum CgA was normal but serum NSE was also increased. Similar to a previous case, we can speculate that serum CgA was not associated with autonomous tumor secretion, and hence, associated with profound decrease during the AOST. Thus, we suggest that AOST may not be accurate in patients with G3 NEC and patients with increased NSE indicating aggressive biology. However, further studies are needed to elucidate this issue.
On the other hand, it is a bit difficult to explain falsepositive results of the AOST. MRI of the abdomen and thorax and 99m Tc-Tektrotyd scintigraphy failed to identify NEN in a 24-year-old female patient with a paradoxical rise in serum CgA during the AOST. We repeated the AOST in this patient 6 months after the initial testing. During the last AOST, her dermatitis-associated symptoms were still present and her baseline serum CgA increased to 748 ng/ mL. However, it decreased to 202 ng/mL at the end of the AOST, which suggests absence of NEN (these data have not been added to the current analysis).
Several points need to be addressed when discussing the potential clinical utility of the AOST. First of all, we must highlight that this is a proof-of-concept study and that our results need to be validated in a different cohort prior to its use in clinical practice. We would like to propose a few suggestions when planning future studies with the AOST. Ideally, future studies should be multicentric and should include only patients with well-differentiated NENs. Patients with poorly differentiated morphology and increased serum NSE or other tumor markers should be excluded, because our data suggest that these patients do not exhibit autonomous CgA secretion associated with NEN, leading to an increased rate of false-negative results. Moreover, the AOST should be repeated in each patient with a different octreotide dose (0.1 and 0.5 mg), in order to find the dose which provides the highest sensitivity and specificity of the AOST. We suggest measuring serum CgA at both the 3rd and 6th hour of the test AOST was defined as positive if patients with normal baseline serum CgA had a decrease in serum CgA at the 3rd hour of >17.6% and if patients with increased baseline serum CgA had a decrease at the 6th hour of >51.3%. due to a significant difference in diagnostic performance at each time point with regard to baseline serum CgA concentration. Finally, the AOST should be performed with different assays for CgA measurement before its wider use in everyday clinical practice.
In conclusion, our pilot study suggests that the AOST is a safe and accurate method which may substantially improve the role of CgA as a screening tool for detecting NENs. In patients with increased baseline serum CgA, the decrease in serum CgA at the 6th hour of the AOST of < 51.3% had 91% diagnostic accuracy, while the decrease in serum CgA at the 3rd hour of the AOST of < 17.6% had 79% diagnostic accuracy in patients with normal baseline serum CgA. Hence, we can conclude that patients with NEN have a less pronounced decrease in serum CgA during the AOST. Further validation studies are needed in order to implement this test in everyday clinical practice.
